# FES-Rowing Versus Zoledronic Acid to Improve Bone Health in Spinal Cord Injury (SCI)

> **NCT01426555** · PHASE2,PHASE3 · TERMINATED · sponsor: **Antonio Lazzari** · enrollment: 70 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **OTHER:** FES-Rowing
- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT01426555
- **Lead sponsor:** Antonio Lazzari
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** Incomplete data set \& analysis
- **Last updated:** 2016-04-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01426555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01426555, "FES-Rowing Versus Zoledronic Acid to Improve Bone Health in Spinal Cord Injury (SCI)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01426555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*